Naoko Takebe

Naoko Takebe

UNVERIFIED PROFILE

Are you Naoko Takebe?   Register this Author

Register author
Naoko Takebe

Naoko Takebe

Publications by authors named "Naoko Takebe"

Are you Naoko Takebe?   Register this Author

73Publications

2041Reads

33Profile Views

Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.

Nat Rev Clin Oncol 2020 04 2;17(4):204-232. Epub 2019 Dec 2.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0293-2DOI Listing
April 2020

A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.

Clin Pharmacol Ther 2019 10 29;106(4):803-809. Epub 2019 Apr 29.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Rockville, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1442DOI Listing
October 2019

Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials.

Eur J Cancer 2019 07 24;115:111-119. Epub 2019 May 24.

Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.04.023DOI Listing
July 2019

Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.

Cancer J 2019 Jul/Aug;25(4):296-299

Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000392DOI Listing
July 2019

Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox.

Cancers (Basel) 2019 Jul 31;11(8). Epub 2019 Jul 31.

Early Clinical Trials Development, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11081087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721450PMC
July 2019

Precision medicine in oncology.

Curr Probl Cancer 2017 May - Jun;41(3):163-165. Epub 2017 Jan 24.

The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Department of thoracic/head and neck medical oncology, Houston, TX.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01470272163020
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2017.01.001DOI Listing
March 2019

Pediatric oncology enters an era of precision medicine.

Curr Probl Cancer 2017 May - Jun;41(3):194-200. Epub 2017 Feb 1.

Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2017.01.002DOI Listing
March 2018

Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.

Curr Probl Cancer 2017 May - Jun;41(3):182-193. Epub 2017 Feb 11.

Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2017.02.001DOI Listing
March 2018

Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.

Curr Probl Cancer 2017 May - Jun;41(3):201-211

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01470272173008
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2017.05.003DOI Listing
March 2018

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.

Cancer Sci 2018 Jan 8;109(1):207-214. Epub 2017 Dec 8.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Rockville, MD, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13436
Publisher Site
http://dx.doi.org/10.1111/cas.13436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765308PMC
January 2018

Drug delivery of oral anti-cancer fluoropyrimidine agents.

Expert Opin Drug Deliv 2017 12 11;14(12):1355-1366. Epub 2017 Apr 11.

h Department of Neurosurgery , Miyagi Cancer Center , Natori , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425247.2017.1316260DOI Listing
December 2017

Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.

Gastric Cancer 2017 May 10;20(3):481-488. Epub 2016 Aug 10.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-016-0629-xDOI Listing
May 2017

Drug induced interstitial lung disease in oncology phase I trials.

Cancer Sci 2016 Dec;107(12):1830-1836

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Rockville, Maryland, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13087
Publisher Site
http://dx.doi.org/10.1111/cas.13087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198943PMC
December 2016

Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

Semin Radiat Oncol 2016 10 15;26(4):271-80. Epub 2016 Jun 15.

Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semradonc.2016.06.005DOI Listing
October 2016

Perspectives on research activity in the USA on Cancer Precision Medicine.

Jpn J Clin Oncol 2016 Feb 2;46(2):106-10. Epub 2015 Nov 2.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyv162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751220PMC
February 2016

Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach.

Chin Clin Oncol 2016 Feb;5(1)

37 Convent Drive, Bldg. 37/Rm.1048, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/9173/9877
Publisher Site
http://dx.doi.org/10.3978/j.issn.2304-3865.2016.01.02DOI Listing
February 2016

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.

J Clin Oncol 2015 Dec 2;33(36):4284-92. Epub 2015 Nov 2.

Daniel V.T. Catenacci, Theodore Karrison, James Wallace, Mark Kozloff, Peng Xu, Les Henderson, Ravi Salgia, Walter M. Stadler, Hedy L. Kindler, University of Chicago Medical Center; Patrick Stiff, Loyola University Medical Center, Chicago; Robert Marsh, Northshore University Health System, Evanston; James Wallace, Mark Kozloff, Ingalls Hospital, Harvey; James Wade, Decatur Memorial Hospital, Decatur; Pankaj Kumar, Oncology/Hematology Associates, Peoria, IL; Melissa R. Junttila, Xi Wang, and Frederic J. de Sauvage, Genentech, South San Francisco; Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Nathan Bahary, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Margit N. Horiba, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Sreenivasa R. Nattam, Ft Wayne Medical Oncology/Hematology, Ft Wayne, IN; Lakshmi Rajdev, Montefiore Medical Center, Bronx; Deirdre Cohen, New York University Cancer Center, New York, NY; Bethany Sleckman, St John's Mercy Medical Center, St Louis, MO; and Naoko Takebe, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.8719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678179PMC
December 2015

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Am Soc Clin Oncol Educ Book 2014 :71-6

From the Division of Cancer Treatment and Diagnosis, National Cancer Institute at the National Institutes of Health, Bethesda, MD; Center for Cancer Genomics, National Cancer Institute at the National Institutes of Health, Bethesda, MD; and Leidos Corporation, Frederick, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.71DOI Listing
November 2015

Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.

Jpn J Clin Oncol 2015 Nov 29;45(11):1001-6. Epub 2015 Sep 29.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjc
Publisher Site
http://dx.doi.org/10.1093/jjco/hyv144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635628PMC
November 2015

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Nat Rev Clin Oncol 2015 Aug 7;12(8):445-64. Epub 2015 Apr 7.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive MSC9739, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520755PMC
August 2015

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

J Clin Oncol 2015 Aug 13;33(24):2646-54. Epub 2015 Jul 13.

Giles W. Robinson, Brent A. Orr, Gang Wu, Tong Lin, Ibrahim Qaddoumi, Sue C. Kaste, Michael Rusch, Sariah J. Allen, Arzu Onar-Thomas, Clinton F. Stewart, James M. Boyett, Richard J. Gilbertson, David W. Ellison, and Amar Gajjar, St Jude Children's Research Hospital, Memphis, TN; Sridharan Gururangan and Annick Desjardins, Duke University Medical Center, Durham, NC; Roger J. Packer, Children's National Medical Center, Washington, DC; Stewart Goldman, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Michael D. Prados, University of California San Francisco, San Francisco, CA; Murali Chintagumpala, Texas Children's Cancer Center, Houston, TX; Naoko Takebe, National Cancer Institute, Bethesda, MD; Maryam Fouladi, Cincinnati Children's Hospital, Cincinnati, OH; and Tom Curran, Children's Hospital of Philadelphia, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534527PMC
August 2015

Biomarkers: exceptional responders-discovering predictive biomarkers.

Nat Rev Clin Oncol 2015 Mar 17;12(3):132-4. Epub 2015 Feb 17.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive MSC9739, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.19DOI Listing
March 2015

Notch1 phenotype and clinical stage progression in non-small cell lung cancer.

J Hematol Oncol 2015 Feb 6;8. Epub 2015 Feb 6.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-014-0104-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343190PMC
February 2015

Targeting notch signaling pathway in cancer: clinical development advances and challenges.

Pharmacol Ther 2014 Feb 27;141(2):140-9. Epub 2013 Sep 27.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2013.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982918PMC
February 2014

Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.

Clin Cancer Res 2013 Nov 27;19(22):6305-12. Epub 2013 Sep 27.

Authors' Affiliations: Departments of Oncology, Pharmaceutical Sciences, Pathology, Radiological Sciences, Biostatistics, and Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee; Center for Neuroscience Research, Children's National Medical Center, Washington, DC; Division of Hematology-Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Texas Children's Hospital, Houston, Texas; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland; and Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856244PMC
November 2013

Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence.

Chin J Cancer Res 2012 Dec;24(4):257-8

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, USA.

View Article

Download full-text PDF

Source
http://www.cjcrcn.org/article/html_1107.html
Publisher Site
http://dx.doi.org/10.3978/j.issn.1000-9604.2012.09.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551324PMC
December 2012

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.

J Biol Chem 2012 Jun 8;287(26):22408-17. Epub 2012 May 8.

Molecular Radiation Therapeutics Branch Support, SAIC-Frederick, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112.357301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381200PMC
June 2012

Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.

Breast Cancer Res 2011 Jun 10;13(3):211. Epub 2011 Jun 10.

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Rockville, Maryland 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218933PMC
June 2011

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.

Nat Rev Clin Oncol 2011 Feb 14;8(2):97-106. Epub 2010 Dec 14.

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, EPN7131, 6130 Executive Boulevard, Rockville, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2010.196
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2010.196DOI Listing
February 2011

Principles and current strategies for targeting autophagy for cancer treatment.

Clin Cancer Res 2011 Feb;17(4):654-66

Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075808PMC
February 2011

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Cancer Chemother Pharmacol 2010 Nov 18;66(6):1079-85. Epub 2010 Feb 18.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1265-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945625PMC
November 2010

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

J Clin Oncol 2010 Oct 20;28(30):4609-15. Epub 2010 Sep 20.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.30.5474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974341PMC
October 2010

Molecular conversations and the development of the hair follicle and basal cell carcinoma.

Cancer Prev Res (Phila) 2010 Oct 21;3(10):1217-21. Epub 2010 Sep 21.

Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, Maryland 20892-7426, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992967PMC
October 2010

Targeting the Hedgehog pathway in cancer.

Ther Adv Med Oncol 2010 Jul;2(4):237-50

Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834010366430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126020PMC
July 2010

Controversies in cancer stem cells: targeting embryonic signaling pathways.

Clin Cancer Res 2010 Jun 8;16(12):3106-12. Epub 2010 Jun 8.

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-09-2934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207800PMC
June 2010

NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.

Gynecol Oncol 2010 Feb 3;116(2):177-80. Epub 2009 Nov 3.

National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.10.046DOI Listing
February 2010

Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell fractions.

Transfusion 2009 Sep 20;49(9):1911-6. Epub 2009 May 20.

Greenebaum Cancer Center and Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1537-2995.2009.02227.x
Publisher Site
http://dx.doi.org/10.1111/j.1537-2995.2009.02227.xDOI Listing
September 2009

RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development.

Clin Cancer Res 2008 Jun;14(12):3948-55

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5152DOI Listing
June 2008

Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact.

Growth Factors 2007 Jun;25(3):141-50

Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08977190701671662DOI Listing
June 2007

Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites.

Leuk Res 2005 Jun 20;29(6):715-8. Epub 2005 Apr 20.

University of Maryland, School of Medicine, Department of Medicine, 22 South Greene Street Baltimore, MD 21201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2004.12.005DOI Listing
June 2005

Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.

Cancer Gene Ther 2002 Mar;9(3):308-20

Program of Molecular Pharmacology and Experimental Therapeutics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.cgt.7700443DOI Listing
March 2002